Compare Futu Holdings Ltd (FUTU) vs Hims and Hers Health Inc (HIMS) Price & Performance

Futu Holdings Limited (FUTU) trades at $109.02, up 4.31% today, with a bullish technical signal from moving averages and strong support at $106. The company reported robust 2025 revenue of $22.85 billion and net income of $11.34 billion, with a high net margin of 49.62%. Valuation ratios appear reasonable, with a P/E of 12.07 and P/S of 5.05. However, recent earnings misses in Q1 2026 and a securities class action lawsuit deadline on August 25, 2026, introduce near-term uncertainty.

The outlook for FUTU is mixed: strong profitability and analyst buy ratings (58% consensus) support upside, but legal risks and earnings volatility pose challenges. Investors should weigh solid fundamentals against regulatory and litigation headwinds, with technical levels suggesting $111 as immediate resistance.

Hims & Hers Health stock trades at $31.59, up 6.51% today, showing strong momentum. The technical outlook is bullish, with the price above key moving averages and support at $30. Fundamentally, revenue growth is robust at 40% year-over-year in Q2 2026 (MarketBeat, 2026-08-10), but profitability remains challenged with a net loss margin of -0.56% in 2026. The company raised its annual revenue forecast to $3.1–3.3 billion (WSJ, 2026-08-10), reflecting confidence in subscriber growth and expansion into weight-loss treatments.

The investment outlook is mixed: strong revenue growth and bullish analyst targets near $35.60 offer upside, but high valuation ratios (P/E of 57.14) and recent earnings misses heighten risk. Key risks include margin pressure from GLP-1 investments and ongoing legal investigations. Wall Street sentiment is cautious, with 65% hold ratings, suggesting patience for profitability improvements.